2021
DOI: 10.1101/2021.09.16.460577
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma

Abstract: Formyl peptide receptor (FPR) family members have been reported to play important role in the resolution of inflammation. A few FPR2/FPR1 dual agonists are reported in the public domain for their anti-inflammatory properties. None of these molecules, however, have been successful as a therapy yet. Recent reports bring forward the ambiguous role of FPR1 in inflammation. These include both positive and negative outcomes. We, therefore, aimed to develop selective FPR2 agonists and evaluated their potential in mit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 42 publications
0
1
0
Order By: Relevance
“…It is also important to assess the efficacy of Ashwagandha in chronic models of airway inflammation, bronchial asthma in animals ( Arora et al, 2021 ; Arora et al, 2022 ; Arora et al, 2022 ; Arora et al, 2022 ; Visaga et al, 2022 ), and subsequently in the COPD and COVID-19 patients.…”
Section: Discussionmentioning
confidence: 99%
“…It is also important to assess the efficacy of Ashwagandha in chronic models of airway inflammation, bronchial asthma in animals ( Arora et al, 2021 ; Arora et al, 2022 ; Arora et al, 2022 ; Arora et al, 2022 ; Visaga et al, 2022 ), and subsequently in the COPD and COVID-19 patients.…”
Section: Discussionmentioning
confidence: 99%